Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2021
Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer disease and mild cognitive impairment
9 September 2021 - In June 2021, the US FDA granted accelerated approval for aducanumab to treat patients with mild cognitive ...
Posted by Michael Wonder on 09 Sep 2021
Biden Administration unveils plan to cut prescription drug prices
9 September 2021 - The Department of Health and Human Services plan supports legislation to empower the government to negotiate Medicare ...
Posted by Michael Wonder on 04 Sep 2021
Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?
3 September 2021 - As Democrats design a way to use the government’s leverage to lower drug prices for seniors, ...
Posted by Michael Wonder on 25 Aug 2021
Don’t meddle with Medicare to save a budget
25 August 2021 - House Democrats this week approved a $3.5 trillion budget framework that has already passed the Senate. ...
Posted by Michael Wonder on 18 Aug 2021
COVID-19 vaccines additional doses: codes & payment
16 August 2021 - The FDA amended the emergency use authorisations for both the Pfizer BioNTech COVID-19 vaccine and the ...
Posted by Michael Wonder on 11 Aug 2021
Medicare expansion and a lower eligibility age are included in Democrats’ $3.5 trillion budget plan
9 August 2021 - There’s no guarantee that these proposals will make it through the full legislative process. ...
Posted by Michael Wonder on 10 Aug 2021
Characterisation of the pharmaceutical risk sharing arrangement process in Catalonia
10 August 2021 - Pharmaceutical risk sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines ...
Posted by Michael Wonder on 05 Aug 2021
G1 Therapeutics granted new technology add-on payment for Cosela (trilaciclib) by CMS
4 August 2021 - G1 Therapeutics today announced that CMS has granted a new technology add-on payment for Cosela (trilaciclib ...
Posted by Michael Wonder on 21 Jul 2021
Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage
21 July 2021 - U.S. hospitals that were expected to be early adopters of Biogen’s Alzheimer’s drug have treated only a ...
Posted by Michael Wonder on 19 Jul 2021
CMS proposes rule to increase price transparency, access to care, safety & health equity
19 July 2021 - The Centers for Medicare & Medicaid Services is proposing actions to address the health equity gap, ...
Posted by Michael Wonder on 19 Jul 2021
Will CMS find aducanumab reasonable and necessary for Alzheimer disease after FDA approval?
19 July 2021 - The recent US FDA approval of aducanumab for the treatment of Alzheimer disease triggered both praise and ...
Posted by Michael Wonder on 12 Jul 2021
CMS opens national coverage determination analysis on treatment for Alzheimer’s disease
12 July 2021 - Today, the Centers for Medicare & Medicaid Services is opening a National Coverage Determination analysis, a ...
Posted by Michael Wonder on 07 Jul 2021
Sanders, progressives face split with centrists over plan to cut drug prices in Medicare
7 July 2021 - Those seeking bipartisan measure say empowering Medicare to negotiate for lower prices could hurt innovation. ...
Posted by Michael Wonder on 06 Jul 2021
Costco could have saved Medicare $2.6 billion in drug spending, analysis shows
6 July 2021 - Medicare spent billions more money on generic drugs for its beneficiaries than warehouse chain Costco did ...
Posted by Michael Wonder on 04 Jul 2021
Medicare ‘coverage with evidence development’ for aducanumab? How might it work?
30 June 2021 - In the wake of the FDA’s controversial decision to approve aducanumab for Alzheimer’s disease, how will, and ...